Evidence map›Paper›PMID 38395466›Full record

ArticleBMJ case reports2024

Diffuse Pneumonitis after Lutetium-177-PSMA-617 Treatment in a Patient with Metastatic Castration-Resistant Prostate Cancer.

John S Wang, Terence Wong, Kevin A Wu, Trey C Mullikin, Andrew Armstrong

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Recurrent pulmonary lymphangitis carcinomatosis detected onEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

John S WangDepartment of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.ORCID http://orcid.org/0000-0002-7191-0437
Terence WongDepartment of Radiology, Division of Nuclear Medicine and Radiotheranostics, Duke University, Durham, North Carolina, USA.
Kevin A WuDepartment of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
Trey C MullikinDepartment of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA.
Andrew ArmstrongDepartment of Medicine, Duke University School of Medicine, Durham, North Carolina, USA andrew.armstrong@duke.edu.
Duke University · USDuke Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present the case of a patient with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) who received lutetium Lu-177 vipivotide tetraxetan (also known as

Indexed as

DipeptidesHeterocyclic Compounds, 1-RingPneumoniaProstatic Neoplasms, Castration-ResistantRadioisotopesHumansLutetiumMaleProstate-Specific AntigenRadiopharmaceuticalsTreatment OutcomeDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177Prostate-Specific AntigenPSMA-617RadioisotopesRadiopharmaceuticalsdrug interactionsprostate cancerradiotherapysafety

Identifiers

PMID38395466
PMCPMC10895240
OpenAlexW4392095784

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.